|Bid||291.80 x 0|
|Ask||293.65 x 0|
|Day's Range||287.30 - 293.60|
|52 Week Range||174.68 - 308.00|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 01, 2023 - Feb 06, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Biogen had been a sinking ship following its Alzheimer’s flop, but positive results in September have changed the company’s trajectory.
The veteran pharmaceutical executive takes charge after the failed launch of Biogen’s once-promising Alzheimer’s disease drug Aduhelm.
Distinguished Industry Leader Brings Extensive International Experience in Large Pharmaceutical and Entrepreneurial Biotech Companies Christopher A. Viehbacher Christopher A. Viehbacher CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ: BIIB) today announced that its Board of Directors has appointed Christopher A. Viehbacher as President and Chief Executive Officer and a member of the Board of Directors, effective November 14. Viehbacher succeeds Michel Vounatsos, who has l